Details of the Drug

General Information of Drug (ID: DMVWLET)

Drug Name
ABBV-154
Indication
Disease Entry ICD 11 Status REF
Crohn disease DD70 Phase 2 [1]
Rheumatoid arthritis FA20 Phase 2 [2]
Drug Type
Antibody drug conjugate
Cross-matching ID
TTD ID
D2AQW7
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Tumor necrosis factor (TNF) TTF8CQI TNFA_HUMAN Not Available [3]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 ClinicalTrials.gov (NCT05068284) A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of ABBV-154 in Subjects With Moderately to Severely Active Crohn's Disease (CD): AIM-CD. U.S.National Institutes of Health.
2 ClinicalTrials.gov (NCT04888585) A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of ABBV-154 in Subjects With Moderately to Severely Active Rheumatoid Arthritis With Inadequate Response to Biologic and/or Targeted Synthetic Disease-Modifying Anti-Rheumatic Drugs (b/tsDMARDs). U.S.National Institutes of Health.
3 Discovery of ABBV-154, an anti-TNF Glucocorticoid Receptor Modulator Immunology Antibody-Drug Conjugate (iADC). J Med Chem. 2023 Sep 14;66(17):12544-12558.